GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Equity-to-Asset

Fortress Biotech (FRA:CNB1) Equity-to-Asset : 0.14 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Fortress Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €20.67 Mil. Fortress Biotech's Total Assets for the quarter that ended in Dec. 2023 was €153.62 Mil. Therefore, Fortress Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.14.

The historical rank and industry rank for Fortress Biotech's Equity-to-Asset or its related term are showing as below:

FRA:CNB1' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.01   Med: 0.22   Max: 0.79
Current: 0.14

During the past 13 years, the highest Equity to Asset Ratio of Fortress Biotech was 0.79. The lowest was 0.01. And the median was 0.22.

FRA:CNB1's Equity-to-Asset is ranked worse than
80.96% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:CNB1: 0.14

Fortress Biotech Equity-to-Asset Historical Data

The historical data trend for Fortress Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Equity-to-Asset Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.30 0.27 0.14 0.14

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.10 0.11 0.14

Competitive Comparison of Fortress Biotech's Equity-to-Asset

For the Biotechnology subindustry, Fortress Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Equity-to-Asset falls into.



Fortress Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Fortress Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=20.673/153.621
=0.13

Fortress Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=20.673/153.621
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortress Biotech  (FRA:CNB1) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Fortress Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines